Biopharmaceuticals - large molecule LC-MS / HR-MS

BioMSTM – Mass spectrometry for the quantification of proteins

Our pioneering application of mass spectrometry based methodologies for the quantitation of biologicals gave rise to LGC’s BioMSTM service. BioMSTM provides a complementary technique to enzyme-linked immunosorbent assays (ELISA) enabling both top-down (analysis of intact proteins) and bottom-up (analysis of proteolytically cleaved fragments) approaches.

We have now been working in this field for over 10 years and have created a robust workflow for the rapid, accurate protein quantitation. It brings a number of advantages to our clients;

  • Eliminates the need for synthesis of antibodies
  • Shorter assay development times
  • Wider dynamic range
  • Improved specificity

 

Our capabilities include the latest mass spectrometry instrumentation and our experience includes many study and molecule types;

  • Monoclonal antibody (mAbs including bispecific antibodies) quantification in biological matrices with or without protein level sample purification
  • Fusion protein quantification using immunoaffinity capture sample clean up
  • Endogenous protein quantification and characterisation
  • Degradation Investigations
  • Peptide Quantification
  • Antibody Drug Conjugate (ADC) total mAb, conjugated and free drug and DAR determination